SCHEMBL5496816

SCHEMBL5496816

Cc1ccc(C(=O)Nc2cc(C(F)(F)F)ccc2N(C)C)cc1-c1ccc2ncnc(N)c2c1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.49
LCK P06239 14/20 0.49
MAPK14 Q16539 14/20 0.49
JAK3 P52333 13/20 0.49
TEK Q02763 4/20 0.49
MAP4K4 O95819 1/20 0.46
BRAF P15056 1/20 0.45
SRC P12931 1/20 0.44
TYK2 P29597 1/20 0.44
SYK P43405 1/20 0.44
BTK Q06187 1/20 0.44
DDR2 Q16832 2/20 0.43
RAF1 P04049 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5497160 0.90 KDR (0.51) KDRLCKMAPK14JAK3TEK
SCHEMBL5498971 0.89 KDR (0.55) KDRLCKMAPK14JAK3TEK
SCHEMBL5498149 0.87 KDR (0.51) KDRLCKMAPK14JAK3TEK
SCHEMBL14568167 0.86 LCK (0.50) KDRLCKMAPK14JAK3TEK
SCHEMBL5501957 0.86 LCK (0.50) KDRLCKMAPK14JAK3TEK
SCHEMBL5502251 0.85 KDR (0.49) KDRLCKMAPK14JAK3TEK
SCHEMBL5494695 0.85 KDR (0.67) KDRLCKMAPK14JAK3TEK
SCHEMBL5499035 0.84 KDR (0.68) KDRLCKMAPK14JAK3TEK
SCHEMBL5494397 0.83 LCK (0.70) KDRLCKMAPK14JAK3TEK
SCHEMBL5496987 0.83 LCK (0.72) KDRLCKMAPK14JAK3TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP disclosed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 KDR 1044/4885LCK 106/4885MAPK14 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.